AHA Logo and Scientific Sessions logo

Visit SomaLogic at the AHA Scientific Sessions 2022

November 5–7, booth 2114

Empowering transformative research and healthcare

Image of scientist testing blood samples

For life sciences researchers

Deepen your CVD research with multi-biomarker discovery, validation, and development in a single platform and realize every sample’s full potential.

Image of physician

For healthcare providers

SomaSignal™ tests expose early biologic signs that a patient may be headed for a severe health event, revealing whether existing treatments are adequately reducing risk or if adaptations are needed.

Session type Session title Presenter
Abstract Oral Session Stroke Council Award – Top Scientific Research in Stroke

11/7/2022
8am – 9am

Heather Dark, NIA

Abstract control #13280

Presentation #396

Abstract Poster Session Unearthing the Complex Relationship Between Adipokines, Biomarkers, and Cardiometabolic Health

11/5/2022

11am – 12pm

Emma Troth

Abstract control #12671

Presentation #SA3001

Abstract Poster Session Observations in Clinical Outcomes from the COVID-19 Pandemic Frontlines 2

11/6/2022
3:45pm – 4:45pm

Michael Hinterberg

Abstract control #12132

Presentation #SU2115

Rapid Fire Oral Session Understanding and Modifying Cardiovascular Risk in Diabetes

11/7/2022
1pm – 1:50pm

Rachel Ostroff

Abstract control #11650

Presentation #610

Abstract Poster Session Biomarkers in Heart Failure: Prognostic Indicators and Mechanistic Research

11/6/2022
3:45pm – 4:45pm

Teun Petersen

Presentation #SU2184

Discover new data from your clinical samples with powerful protein profiling

  • SomaScan® Assay – Measure 7,000 proteins over a 10-log dynamic range (from fM to µM) with coefficients of variation <5%
  • SomaScan Panels – Create a custom panel or choose from disease-specific panels, including CVD and Inflammation/Immune Response
  • SomaSignal tests – 21 quantitative clinical metrics from a 55-µL sample of blood, urine, CSF, or other body fluids

Learn more

Our cardiovascular tests include:

  • CardioDMTM – Predicts the absolute risk of a cardiovascular event within 4 years, for patients over 40, with type 2 diabetes, with or without cardiovascular disease or chronic kidney disease.
  • Primary Cardiovascular Risk – 4 years – Likelihood of having a cardiovascular event (MI, stroke, heart failure-related hospitalization, cardiac death) within 4 years for patients with no prior history of cardiovascular disease.
  • Secondary Cardiovascular Risk – 4 years – Predicts the absolute risk of a cardiovascular event within 4 years, for patients 40 years and older, with stable cardiovascular disease, with or without Type 2 Diabetes, chronic kidney disease, or non-acute symptoms for suspected coronary artery disease.
  • Cardiovascular Risk in Patients Over 65 – Predicts the absolute risk of a cardiovascular event within 4 years, for patients older than 65 years, without known cardiovascular disease, with or without Type 2 Diabetes
  • Heart Failure Prognosis – HFpEF – Predicts the risk of all-cause death within 12 months in patients over 18, with stable heart failure and preserved ejection fraction (HFpEF).
  • Heart Failure Prognosis – HFrEF – Predicts the risk of all-cause death within 12 months in patients over 18, with stable heart failure and reduced ejection fraction (HFrEF).

Learn more